GlassScriptPhysician profile
Anamika Shukla
NPI 1184895468
$3,297.15
in general payments reported to CMS, 2019-2025
31 companies · $514 in 2025
The $514 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $465 · 2022: $789 · 2023: $1,021 · 2024: $508 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,043.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $547.01 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $462.23 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $324.39 | 2022-2025 | Repatha, Otezla, Repatha |
| Nestle Healthcare Nutrition INC. | $280.62 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $223.63 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.46 | 2021-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Glaxosmithkline, LLC. | $140.69 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $122.18 | 2021-2022 | |
| Amarin Pharma, INC. | $96.78 | 2021 | |
| Scilex Pharmaceuticals INC. | $90.82 | 2021-2024 | |
| Lilly USA, LLC | $89.83 | 2021-2024 | Jardiance, Mounjaro |
| Abbvie INC. | $83.69 | 2021-2023 | |
| Dexcom, INC. | $74.11 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.57 | 2023-2024 | Xifaxan |
| Nevro Corp. | $54.41 | 2023 | Senza |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $53.98 | 2023-2025 | Afrezza |
| Ardelyx, INC. | $53.55 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $39.37 | 2025 | Voquezna |
| Exact Sciences Corporation | $37.69 | 2023 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $34.97 | 2024-2025 | Zoryve |
| Shield Therapeutics INC | $32.32 | 2024-2025 | |
| Pulmonx Corporation | $32.30 | 2022 | |
| Mylan Specialty L.P. | $32.23 | 2022-2023 | Yupelri |
| Abbott Laboratories | $31.04 | 2022 | |
| Sanofi-Aventis U.S. LLC | $30.53 | 2021-2023 | |
| Seqirus USA INC | $28.26 | 2025 | Fluad, Flucelvax |
| Amneal Pharmaceuticals LLC | $23.08 | 2023 | Lyvispah |
| Smith+Nephew, INC. | $16.70 | 2024 | Collagenase Santyl |
| Biohaven Pharmaceuticals, INC. | $16.53 | 2021 | |
| Xeris Pharmaceuticals, INC. | $16.47 | 2022 | |
| Genentech USA, INC. | $5.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anamika Shukla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.